ArticleLeukemia2022
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Monika Kaisrlikova et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papertrialcites it